Latest Agomab Therapeutics News & Updates

See the latest news and media coverage for Agomab Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Agomab Therapeutics

Clinical-stage biopharmaceutical company developing fibrosis therapies

agomab.com
Headquarters
Antwerp, Belgium
Founded year
2017
Company type
Private company
Number of employees
60–200

Last updated

Latest news about Agomab Therapeutics

Company announcements

  • Agomab Therapeutics

    Agomab reports 2025 financial results

    Cash at €116.5M extends runway to 2029 with $208M IPO. Confirms Phase 2b/2 trials and topline data in H2 2026.

  • Agomab Therapeutics

    Agomab receives U.S. patent for AGMB-447

    The patent covers the inhaled ALK5 inhibitor in Phase 1b for IPF, providing IP protection through 2041. CEO highlights it as a key milestone.

  • Agomab Therapeutics

    Agomab Therapeutics presents positive Phase 2a results

    Nature Reviews highlights their ontunisertib presentation for Fibrostenosing Crohn’s disease at ECCO'26 Congress.

  • Agomab Therapeutics

    Agomab announces closing of IPO

    The offering raised $200 million from 12.5 million ADSs at $16 each. ADSs trade on Nasdaq as AGMB.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Agomab Therapeutics

Track Agomab Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agomab Therapeutics competitors & trending companies

Browse news for competitors to Agomab Therapeutics and other trending companies.